Hsbc Holdings PLC Takes $1.01 Million Position in Radiopharm Theranostics Limited – Sponsored ADR $RADX

Hsbc Holdings PLC bought a new stake in Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 191,624 shares of the company’s stock, valued at approximately $1,007,000. Hsbc Holdings PLC owned approximately 1.62% of Radiopharm Theranostics at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in RADX. Virtu Financial LLC acquired a new stake in Radiopharm Theranostics in the fourth quarter valued at approximately $76,000. Jane Street Group LLC bought a new stake in shares of Radiopharm Theranostics during the fourth quarter valued at approximately $76,000. Finally, Marex Group plc acquired a new position in shares of Radiopharm Theranostics during the fourth quarter worth approximately $54,000.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on RADX shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Radiopharm Theranostics in a report on Tuesday, April 21st. HC Wainwright started coverage on shares of Radiopharm Theranostics in a report on Thursday, June 4th. They set a “buy” rating and a $6.00 price objective on the stock. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Radiopharm Theranostics presently has an average rating of “Hold” and an average price target of $11.00.

View Our Latest Stock Report on Radiopharm Theranostics

Radiopharm Theranostics Price Performance

NASDAQ RADX opened at $4.33 on Tuesday. The business has a fifty day simple moving average of $4.40 and a 200 day simple moving average of $4.68. Radiopharm Theranostics Limited – Sponsored ADR has a 12 month low of $3.62 and a 12 month high of $16.25.

About Radiopharm Theranostics

(Free Report)

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.

Recommended Stories

• Five stocks we like better than Radiopharm Theranostics
• The SK Hynix IPO and 2027’s AI Memory Squeeze
• Meta Platforms Stock Rises as Muse Spark 1.1 AI Model Debuts
• Why Welltower’s Growth Story Might Outrun Its Rich Valuation
• One Short- and One Long-Term ETF for Quantum Computing Bulls

Want to see what other hedge funds are holding RADX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX – Free Report).